A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Sponsor
Zhejiang Cancer Hospital
Study ID
NCT05247619
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Efficacy and safety of Tislelizumab combined with Bevacizumab and chemotherapy in patients with persistent, recurrent or metastatic cervical cancer.

Key Dates

First listed
Feb 21, 2022
Start date
Jun 30, 2022
Status verified
Jul 2022
Primary completion
Aug 31, 2024
Completion
Jan 31, 2025

Study Design

Enrollment
49 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention
    Tislelizumab + Bevacizumab + Paclitaxel + Cisplatin/Carboplatin

Primary Outcome Measure

mPFS [ Time Frame: The time from the first dosing of the study drug until the first objective recording of disease progression or death from any cause, whichever occurred first, up to approximately 24 months. ]

Central Contacts

Related Studies